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Abstract
Topical application of Vitamin K1 has been demonstrated to effectively treat papulopustular
skin rash, a serious and frequently encountered side effect of Epidermal Growth Factor
Inhibitors (EGFRIs). Systemic absorption of vitamin K1 from skin and the resultant conse-
quence of antagonizing EGFRIs anticancer effects jeopardizes the clinical acceptability of
this rather effective treatment. The purpose of the present study was to rationally formulate
and evaluate the release rate and transdermal absorption of a wide range of Vitamin K1 der-
mal preparations with a variety of physiochemical properties. A library of 33 formulations
with were compounded and tested for Vitamin K1 permeation using hydrophobic mem-
branes and porcine skin mounted in a Fran diffusion cells. Our results demonstrate the low-
est diffusion for water-in-oil emulsions, which also demonstrated a negligible transdermal
absorption. The statistical analysis showed a significant correlation between in vitro and ex
vivo results. While viscosity did not have a significant impact on the diffusion or absorption
of vitamin K1, an increase in the lipid content was correlated with an increase in transmem-
brane diffusion (not with transdermal absorption). Overall, formulation design significantly
impacts the release rate and transdermal absorption of vitamin K1, and confirms the possi-
bility of minimal systemic distribution of this vitamin for this specific purpose.
Introduction
Molecularly-targeted anticancer agents have become increasingly significant in the manage-
ment of many types of cancer in 21st century. This category of anticancer agents mostly target
proteins involved in proliferation and/or survival of cancer cells. One of these proteins is epi-
dermal growth factor receptor (EGFR), which is upregulated in different types of cancer, and
has been the target for a class of anticancer drugs known as EGFR inhibitors (EGFRIs) [1].
EGFRIs include small molecule drugs (e.g., erlotinib and gefitinib) and monoclonal antibodies
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specific to this receptor (e.g., cetuximab and panitumumab), and have been used in combina-
tion with cytotoxic agents with different degrees of success in various types of cancer, includ-
ing colon, rectum, pancreas, and lung cancer [2]. A common side-effect of EGFRIs, however,
is acneiform eruptions known as papulopustular rash, which is seen in more than 50% of
patients (up to 86% for cetuximab), with up to 18% of the patients experiencing a grade 3 reac-
tion, which includes Lesions with symptoms 50% body surface, accompanied with pain, dis-
figurement, ulceration or desquamation [3]. This papulopustular rash mostly affects the upper
trunk, scalp, and face areas [4]. Dry and itchy skin in 12–16% of patients, and microbial infec-
tions in 38–70% are among other cutaneous complications of EGFRI-induced papulopustular
rash. Reactions with severity grading at 2 or above may result in dose reduction, treatment
interruption or discontinuation. These reactions are also associated with worse quality of life
scores, especially in younger patients [5].
While the mechanism of skin toxicity induced by EGFRIs is not completely understood, it
has been suggested that the response to EGFRIs and the survival rate correlate with the degree
of severity and the onset of the skin toxicity [6], which indicates that a similar mechanism of
action could is for therapeutic effect and skin toxicity. More interestingly, the severity of skin
toxicity and the onset of the symptoms seem to be independent of the type of EGFRI used, and
the correlation of toxicity with efficiency of inhibition of EGFR has been reported for small
molecule targeting EGFR, monoclonal antibodies, and combination of both [7]. In 1995, a
study in transgenic mice with dominant negative mutation in EGFR showed that lack of EGFR
activation leads to interfollicular epidermal keratinocyte hyperplasia and necrosis and disap-
pearance of the follicles, accompanied by strong infiltration by inflammatory cells [8]. In a
2002 study on pharmacodynamics of gefitinib (known as ZD1839 at the time), the drug was
detected in skin samples of patients receiving systemic drug, and suppression of EGFR phos-
phorylation was confirmed in all EGFR-expressing cells [9]. The causal relationship between
EGFR inhibition and skin toxicity was further explored in a 2009 review paper that linked the
location of the skin rash (most commonly seen in scalp, face, and upper chest) with high den-
sity of sebaceous glands, where a higher expression of EGFR has been reported [10].
In this study, we investigated the effect of formulation, including water/lipid content, inter-
nal/external phase, surfactant system, and viscosity, on the transdermal absorption of vitamin
K1 ex-vivo. We hypothesized that the characteristics of the formulation can significantly affect
the transdermal absorption of vitamin K1, and our objective was to formulate a topical product
that is capable of limiting biodistribution of vitamin K1 to the skin, and minimize the risk of
systemic absorption. This formulation will be further evaluated in healthy volunteers to con-
firm the in vitro and ex vivo findings reported here.
Materials and methods
Materials
Synthetic vitamin K1 (Phytonadione) was purchased as a raw material from Skin Actives Sci-
entific (Gilbert, AZ), with purity of> 98%. Bees wax, cetaryl alcohol, isopropyl myristate, ses-
ame oil, white petrolatum, polyoxyethylene 23 lauryl ether, polyoxyethylene 2 oleyl ether,
sorbitan monooleate, polyethylene glycol (PEG) 400 monostearate, carbomer 940, poloxamer
407, butylated hydroxytoluene (BHT), imidurea, methylparaben, propylparaben, and polyeth-
ylene glycol were all National Formulary (NF) grade and purchased from Professional Com-
pounding Centers of America (PCCA; Huston, TX). PEG-30 Dipolyhydroxystearate was a gift
from Huntsman Performance Products (Woodlands, TX). Labrasol and Tefose 63 were gifts
from Gattefosse (Paramus, NJ). The Durapore Membrane Filters (0.22-micron GV; catalogue
number: GVWP09050) used for in vitro diffusion test were purchased from EDM Millipore
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(Burlington, MA). The pig skin used for ex-vivo transdermal absorption was excised from
freshly slaughtered pig heads that were obtained from a local slaughterhouse (Lizzie Custom
Processing Slaughter House, 7310 Pine Ave, Chino, CA). 1-Penthanol (99%, extra pure,
ACROS Organics), fetal bovine serum (FBS), and Hank’s Balanced Salt Solution (HBSS) were
obtained from Fisher Scientific (Carlsbad, CA). Cholesteryl benzoate (Catalogue number:
C75802) and anhydrous hexane (95%; catalogue number: 296090) were purchased from Sigma
Aldrich (St. Louis, MO). HPLC vials were provided by Thermo Scientific (Waltham, MA).
Methods
Quantification of vitamin K1. A High-Performance Liquid Chromatography (HPLC)-
based analysis method, based on USP recommended assay, was used to quantify vitamin K1 in
the formulations, and the extracts from receiving phase used for in vitro and ex-vivo experi-
ments. Vitamin K1 was extracted using hexanes:1-penthanol 199:1 mixture. Internal standard
(cholesteryl benzoate; 10 μg/mL) was added to the sample and the mixture of sample and
extraction mixture were vortexed, and centrifuged at 12,000 g for 5 minutes. The hexane-
s:1-pentanol portion was then collected for analysis. The HPLC system consisted of an
Ascentis Si 5um L3 (25cm x 4.6mm) column connected to a Prominance-i Shimadzu Analyti-
cal HPLC. Then 15 μL of extraction was injected onto the column and eluted at a flow rate of
1.0mL/min room temperature under isocratic conditions with hexanes:1-pentanol as the
mobile phase. Vitamin k1 (retention time 8.2 minutes) and internal standard (retention
time 3 minutes) were analyzed at 254nm. Standard curves were created in concentration
range of 10 ng/mL—10 μg/mL, based on the ratio of the area under the curves (AUC; Vitamin
K1 AUC / Internal Standard AUC) vs. concentration. A sample peak for the internal standard
and different vitamin K1 concentrations is presented in S1 Fig. See the S1 File for the valida-
tion of the analytical method.
Topical formulations of vitamin K1. Topical formulations were compounded with the
strength of 0.1% vitamin K1. Even though vitamin K1 is not available in United Sates as a topi-
cal pharmaceutical product, a vitamin K1 topical cream is manufactured in Slovenia by Phar-
madab (with Brand name Reconval K1), which contains 0.1% active ingredient. Also, the
clinical studies on the effect of vitamin K1 on EGFRI-induced folliculitis have been conducted
with a similar strength [11, 12]. The formulations were categorized in 4 general dosage form
categories: a. ointments: semisolids with hydrophobic external phase, including water in oil or
W/O products; b. creams: oil in water or O/W semisolids with aqueous external phase; c.
lotions: O/W or W/O products with thinner consistency; and gels (Table 1). The formulations
were designed to introduce different important variables into the product library: a) Composi-
tion of the dispersion: The formulation library includes oil in oil dispersions (formulations O1
to 3), water in oil dispersions (formulations O.W/O4 to 12 and L.W/O22 to 24), oil in water
dispersions (formulations C.O/W13 to 21 and L.O/W25 to 27), and dispersion of active ingre-
dient in completely aqueous vehicle (formulations G.P28 to 30 and G.C31 to 33). Vitamin K1
is a hydrophobic active ingredient and its dispersion pattern in the formulation would change
depending on the external phase, which could be one of the factors affecting the transdermal
absorption; b) Lipid content: The degree of chemical compatibility of the active ingredient and
the vehicle could affect the release rate, and therefore, the transdermal absorption. Due to
hydrophobic nature of vitamin K1, a wide range of lipid contents were included in the formu-
lation library with both ends of spectrum (0–100% lipid) included.; c) Emulsifier: The emulsi-
fying agent(s) could significantly affect the physical characteristics of the topical dispersions,
and therefore different options, including individual and combinatorial systems, were
explored; and d) Viscosity: According to Fick’s first law of diffusion, the diffusion coefficient,
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or diffusivity, directly affects the diffusion rate, and therefore, the release rate from the dosage
form, and one of the factors affecting diffusion coefficient is the viscosity of the vehicle. There-
fore, the lipid content and composition (proportion of the lipid ingredients that are liquid in
Table 1. Library of formulations studied for dermal delivery of Vitamin K1.
Dosage form Formulation Code Surfactant system† Gelling Agent Lipid content†† Lipid composition‡
Ointment O1 - - 100% CA/WP/BW
O2 - - 100% WP/CA/BW
O3 - - 100% SO/WP/BW/CA/IM
O.W/O4‡‡ polyoxyethylene 2 oleyl ether - 75% WP/CA/SO/IM
O.W/O5 sorbitan monooleate / polyoxyethylene 23 lauryl ether - 75% WP/CA/SO/IM
O.W/O6 PEG-30 Dipolyhydroxystearate - 75% WP/CA/SO/IM
O.W/O7 polyoxyethylene 2 oleyl ether - 67.5% WP/CA/SO/IM
O.W/O8 sorbitan monooleate / polyoxyethylene 23 lauryl ether - 67.5% WP/CA/SO/IM
O.W/O9 PEG-30 Dipolyhydroxystearate - 67.5% WP/CA/SO/IM
O.W/O10 polyoxyethylene 2 oleyl ether - 60% WP/CA/SO/IM
O.W/O11 sorbitan monooleate / polyoxyethylene 23 lauryl ether - 60% WP/CA/SO/IM
O.W/O12 PEG-30 Dipolyhydroxystearate - 60% WP/CA/SO/IM
Cream C.O/W13 polyoxyethylene 23 lauryl ether / polyoxyethylene 2 oleyl ether - 45% SO/WP/CA
C.O/W14 Tefose - 45% SO/WP/CA
C.O/W15 Labrasol - 45% SO/WP/CA
C.O/W16 polyoxyethylene 23 lauryl ether / polyoxyethylene 2 oleyl ether - 37.5% WP/SO/CA
C.O/W17 Tefose - 37.5% WP/SO/CA
C.O/W18 Labrasol - 37.5% WP/SO/CA
C.O/W19 polyoxyethylene 23 lauryl ether / polyoxyethylene 2 oleyl ether - 30% WP/CA/SO
C.O/W20 Tefose - 30% WP/CA/SO
C.O/W21 Labrasol - 30% WP/CA/SO
Lotion L.W/O22 polyoxyethylene 2 oleyl ether - 74% SO/WP/CA/IM
L.W/O23 sorbitan monooleate / polyoxyethylene 23 lauryl ether - 74% SO/WP/CA/IM
L.W/O24 Labrasol - 74% SO/WP/CA/IM
L.O/W25 polyoxyethylene 23 lauryl ether / polyoxyethylene 2 oleyl ether - 21.5% SO/CA/WP/IM
L.O/W26 Tefose - 21.5% SO/CA/WP/IM
L.O/W27 Labrasol - 21.5% SO/CA/WP/IM
Gel G.P28 Labrasol Poloxamer 0% -
G.P29 Tefose Poloxamer 0% -
G.P30 polyoxyethylene 23 lauryl ether / polyoxyethylene 2 oleyl ether Poloxamer 0% -
G.C31 Labrasol Carbomer 0% -
G.C32 Tefose Carbomer 0% -
G.C33 polyoxyethylene 23 lauryl ether / polyoxyethylene 2 oleyl ether Carbomer 0% -
†: The total amount of the surfactant(s) was kept constant among all formulations, regardless of the composition of emulsion and aqueous/lipid ratio.
††: The lipid content is calculated solely based on the ratio of the weight of the lipid ingredients added to create the structure of dosage form and the total weight of the
formulation. The emulsifier(s), antioxidant, preservatives, and active ingredient were not included in the calculations as “lipids”.
‡: The order of the ingredients indicate the percentage of the ingredients included from the highest to lowest percentage.
: According to USP definition (a semisolid dosage form with hydrocarbon external phase)
‡‡: The naming convention is based on the dosage form, and the structure of emulsion (e.g., O.W/O, indicates ointment, water/oil) or gelling agent (e.g., G.C, indicates
gel, Carbomer). The numbers are based on the order of dosage form in the library.
: According to USP definition (a semisolid dosage form with aqueous external phase)
BW: Bees Wax; CA: Cetaryl Alcohol; IM: Isopropyl Myristate; SO: Sesame Oil; WP: White petrolatum
https://doi.org/10.1371/journal.pone.0204531.t001
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ambient temperature) was modified in different formulations to manipulate the viscosity of
the dosage form.
The total emulsifier content was 5% in all water in oil and oil in water dispersions. This
total percentage for emulsifiers was reduced to 2% in poloxamer gel formulations due to emul-
sifying characteristics of poloxamer. The total HLB of the emulsifying system was adjusted at
approximately 5 for W/O, and 12 for O/W emulsions. The ratio of emulsifying agents in the
combinatorial systems were calculated based on the following equation:
Total HLB = [(Proportion of Surfactant A) × (HLB of Surfactant A)] + [(Proportion of Sur-
factant B) × (HLB of Surfactant B)]
All formulations were preserved and contained an antioxidant. For oil in oil dispersions
(formulations O1 to O3), the excipients were melted and mixed, and after cooling down, vita-
min K1 was added and mixed with a homogenizer (Turrax T25, IKA; Medisca, Las Vegas,
NV). The final products were passed through an ointment mill (EXAKT 50EC+; PCCA, Hus-
ton, TX). For water in oil dispersions (formulations O.W/O4 to 12 and L.O/W25 to 27), vita-
min K1 was added to the cooled down mixture of melted lipids, before the aqueous phase was
added to the mixture while being homogenized. The final products were passed through the
mill. A similar protocol was followed for oil in water dispersions, except that the medicated
and cooled mixture of melted lipids was added to the aqueous phase. For gel formulations,
vitamin K1 was mixed with the emulsifier(s) and added to the aqueous phase, before adding
the gelling agent. For carbomer gels, the pH was adjusted to 6–7 with 1 molar NaOH. Poloxa-
mer gels were stored at ambient temperature after completion of compounding procedure.
The viscosity of the randomly selected formulations was determined using a USS-DVT4
Digital Rotary Viscometer at ambient temperature.
In vitro transmembrane diffusion. A set of 6 Franz cells (PermeGear; Hellertown, PA)
was used for in vitro diffusion and permeation studies. For transmembrane diffusion experi-
ments, PVDF 0.22 μ membranes were mounted on the Franz cells, and vitamin K1-containing
formulations were weighed and placed on the membrane (equivalent to 200 μg active ingredi-
ent; in donor chamber). The receiving chamber was filled with approximately 12.5 mL of 30%
FBS mixture in HBSS as the receiving phase, and was stirred with a magnetic rotor and main-
tained at 37˚C for the entire experiment time. One milliliter samples were collected from the
receiving phase at pre-determined time points of 0.5, 2, 6, 12, and 24 hours, and replaced with
same quantity of fresh receiving phase. The vitamin K1 was extracted using the mobile phase,
and the amount of vitamin K1 diffused to the receiving phase was quantified using the HPLC
method described before.
Ex-vivo transdermal absorption. The transdermal permeation of vitamin K1 formula-
tions was tested using the cheek skin obtained from an adult pig. The heads of freshly slaugh-
tered pigs were obtained from a local slaughterhouse and immediately transferred to the lab
on ice. Full thickness patches of about 2 × 2 inches size of intact skin were cut from the cheek
area of the head. The pieces were cleaned of any underlying subcutaneous fat but leaving the
epidermis and dermis both intact. The samples were then rinsed with sterile 1 × PBS, and then
either used immediately or kept in serum free low glucose DMEM in 4˚C for maximum up to
4 days before being used. The skin samples were then mounted between the donor and
receiver compartments of the Franz cell, with the stratum corneum side facing the donor com-
partment and the dermis facing the receiver compartment. The transdermal permeation was
evaluated under similar conditions used for transmembrane diffusion, using the same proto-
col. However, the experiments were conducted for 12 hours (not 24 hours) due to sensitivity
of the extracted skin samples to the temperature used for the test.
Chemical stability. Samples of formulation L.W/023 were stored in three different condi-
tions: 4˚C, away from light; ambient conditions (20–25˚C and natural daylight/laboratory
Topical formulations designed to minimize transdermal absorption of Vitamin K1
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lighting); and 37˚C and 95% relative humidity (RH), away from light. Samples were collected
at pre-determined time points, and the vitamin K1 content was quantified by the described
analytical method.
Statistical analysis. All data points are presented as mean ± standard deviation (SD). The
correlation coefficient was calculated according to Pearson Correlation Coefficient equation,
and its significance was determined by t test. The mean transmembrane diffusion and trans-
dermal absorption among four different categories of formulations were compared by one-
way ANOVA and Tukey post-hoc test (p< 0.05). The box graphs were produced using Graph-
pad Prism 7.04.
Results and discussion
Currently, topical antibiotics and corticosteroids are used to control the symptoms of this
adverse reaction; however, considering the long duration of treatment with EFGRIs, extreme
caution is recommended due to drug resistance and adverse effects associated with long term
use of antibiotics and corticosteroids, respectively [13]. However, due to the potential link
between EGFR inhibition and the skin toxicity, EGFR activators and phosphatase inhibitors
were investigated to protect the skin from the toxic effect of EGFRIs, and menadione (vitamin
K3) was confirmed as a potent EGFR activator in human epidermal keratinocytes in 2006 [14].
In 2008, a topical cream containing 0.1% vitamin K1 (also known as phytomenadione, phyto-
nadione or phylloquinone; a naturally occurring vitamin in certain vegetables) and urea was
used on 30 patients after the cutaneous toxicity was documented, and positive response was
reported for all patients within 18 days [15]. A pilot clinical trial on prophylactic effects of vita-
min K1 cream in patients with metastatic colorectal cancer treated with cetuximab was
reported in 2014, which indicated a possible prophylactic benefit for topical vitamin K1 appli-
cation [11]. Interestingly, a recent placebo-controlled phase II study of vitamin K3 cream
showed no benefit for treatment of cetuximab-induced rash [16]. While vitamin K is com-
monly used in cosmetic products, pharmaceutical topical dosage forms of Vitamin K are not
commercially available in United States.
While the selected HPLC analysis method is based on the recommended method in USP/
NF [17], the method was validated to ensure reliability of the quantification method. The stan-
dard curves consistently showed a linear relationship (r2 > 0.99 throughout the project) in the
selected concentration range (up to 10 μg/mL). The inter- and intra-day comparisons showed
both accuracy and precision in all selected concentrations (S1 Table). The CV% was approxi-
mately 15 or higher for the smallest selected concentration of 0.2 μg/mL, which was signifi-
cantly higher than other concentrations, and indicates this concentration as the limit of
quantification for this method. Also, a simple extraction method using the mobile phase was
used to collect vitamin K1 from the compounded dosage forms and the receiving phase in
transmembrane diffusion and transdermal absorption experiments. The efficiency of the
extraction method was also explored using this HPLC method compared to the calculated con-
centration (in triplicate), and a recovery of more than 98% was repeatedly recorded for oint-
ments, creams, gels, and receiving phase.
The compounded dosage forms were controlled for viscosity and the amount of vitamin
K1. All compounded products contained the calculated amount of 0.1% w/w within 97.5–
102.5%. Table 2 demonstrates the dynamic viscosity of the selected formulations explored in
this study. One formulation was selected from each category. Viscosity of the vehicle is one of
the factors that is speculated to affect the diffusion of the active ingredient and the release rate
from the dosage form [18, 19]. In this study we manipulated the lipid content and the lipid
composition to create a wide range of viscosity among the compounded dosage forms. As
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PLOS ONE | https://doi.org/10.1371/journal.pone.0204531 October 5, 2018 6 / 14
expected decreasing the lipid content was associated with a decrease in viscosity. Furthermore,
using lipid components with low melting point, which are in liquid form at room temperature,
decreased the viscosity significantly, which is evident in comparing the O.W/O5 and L.W/O23
with 75% and 74% lipid contents, respectively, with viscosities of 659 and 357 Pascal-Second,
respectively. The poloxamer gel was significantly more viscous than carbomer gel in this study,
which is at least partially due to the concentration of the gelling agent used in these groups of
formulations. Among the selected formulations, the viscosity of one formulation (O2) was
higher than the maximum quantifiable value for the instrument used, which is reported
as> 1000 Pascal-Second.
For transdermal absorption, the active pharmaceutical ingredient must leave the vehicle,
and therefore, diffusion from the dosage form to a receiving phase through a hydrophobic
membrane was quantified for all designed formulations. PVDF membranes have been fre-
quently used for this type of in vitro evaluation for different therapeutic agents, including
8-methoxypsoralene [20], riboflavin (B₂ vitamin) [21], and doxycycline [22], among others. As
a positive control, 200 μg of pure vitamin K1 oil was placed on the membrane to evaluate the
transmembrane diffusion of the pure active ingredient (in triplicate). After 24 hours,
98.7 ± 1.1% of the vitamin K1 was detected in the receiving phase, which indicates that vitamin
K1 is readily diffused through the membrane.
The objective of PVDF experiments was to characterize diffusion of vitamin K from our
formulations under a simple and controlled setting that offered the advantage of minimal
interexperimental variables. This was especially critical for the initial optimization of our for-
mulations. The intent of PVDF diffusion study was not to extrapolate this data for in vivo skin
permeation. The results of transmembrane diffusion are summarized in Fig 1. At 24-hour
time point, formulations with 100% lipid content and no aqueous phase demonstrated the
highest diffusion compared to other formulations (Fig 1A; Formulation O2 showed the high-
est cumulative distribution of 87.8%; the only other diffusion over 80% was observed for the
W/O ointment formulation O.W/O7 with 85.1%). Overall, formulations in most of the catego-
ries demonstrated similar patterns, with lotions and carbomer gels demonstrating the lowest
diffusion after 24 hours (~15% for W/O emulsions [Fig 1H], ~35% for O/W emulsions [Fig
1I], and ~21% for carbomer gels [Fig 1K]). The only discrepancy was observed for gels: while
poloxamer gels showed relatively high cumulative diffusions (up to 76.8% for G.P30; Fig 1J),
the carbomer gels showed significantly lower diffusion at the 24-hour end-point. This might
Table 2. The dynamic viscosity of selected formulations.
Formulation Lipid content Viscosity (Pascal-second; P.S)
O2 100% > 1000
O.W/O5 75% 659 ± 33
O.W/O8 67.5% 605 ± 9
O.W/O11 60% 571 ± 18
C.O/W14 45% 501 ± 21
C.O/W17 37.5% 474 ± 11
C.O/W20 30% 412 ± 17
L.W/O23 74% 357 ± 17
L.O/W26 21.5% 103 ± 2
G.P29 0% 993 ± 5
G.C32 0% 213 ± 16
: The tests were performed in triplicate, and the data is presented as mean ± standard deviation.
https://doi.org/10.1371/journal.pone.0204531.t002
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be at least partially due to the micelle-forming characteristics of poloxamer, which is a tri-
block co-polymer, and has been used for transdermal delivery of different therapeutic agents
[23, 24]. Nanoscale emulsions have been studied extensively for transdermal delivery [25, 26],
which could partially explain the enhanced diffusion and transdermal absorption observed in
this study with poloxamer gels. The surfactant system did not seem to change the diffusion pat-
tern in each category; however, formulations O.W/O4, O.W/O7 (both emulsified with polyox-
yethylene 2 oleyl ether), C.O/W19, and G.P30 (both emulsified with combination of
polyoxyethylene 2 oleyl ether and polyoxyethylene 23 lauryl ether) showed significantly higher
diffusions at the 24-hour end-point compared to similar formulations prepared with other sur-
factant systems (Fig 1B, 1C, 1G and 1J, respectively). And finally, while most formulations
reached a plateau after 12 hours, W/O ointment O.W/O7 and all poloxamer gels showed sig-
nificant increase in overall diffusion after the 12-hour time point (Fig 1C and 1J).
Ex-vivo transdermal absorption tests were performed using pigs’ cheek skin. Many reports
have indicated structural similarities in pig and human skin including similar thickness, hair
follicle content, pigmentation, collagen and lipid composition, healing mechanism [27], and
even the flux through the skin and concentrations in the skin (in which regard it is more
Fig 1. Transmembrane diffusion. The in vitro transmembrane diffusion profile of the formulation library using Franz cells. Each panel represent a set of three
formulations that shared similar phase composition and lipid content, but differed in surfactant system (n = 3; error bars indicate standard deviation).
https://doi.org/10.1371/journal.pone.0204531.g001
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reliable than commercially available reconstituted skin models) [28]. Similar to transmem-
brane diffusion test, all formulations included in this study were tested for transdermal absorp-
tion. However, due to contamination concerns, the study was only performed up to 12 hours.
Also, despite the differences observed in release rates from different formulations, which could
create a bias in driving force for transdermal absorption, we decided to keep the concentration
of vitamin K1 constant in all formulations. Our objective was to select a formulation for clini-
cal studies that ensures minimum transdermal absorption, and therefore, the selection had to
be made among formulations with similar strengths.
The results of transdermal absorption for the formulation library is summarized in Fig 2.
As expected, the overall extent of transdermal absorption was significantly lower than the dif-
fusion at the same time point. Vitamin K1 is a hydrophobic vitamin with a relatively large mol-
ecule (MW = 451), and therefore not readily absorbed through intact skin. Also, the variability
among different formulations was less significant in this set of studies, which is expected due
to the lower overall levels of absorption. However, considering the almost complete transmem-
brane diffusion of the active ingredient (which indicates sufficient sink conditions and the abil-
ity of the receiving phase to solubilize the diffused portions of the active ingredient), the
Fig 2. Transdermal absorption. The ex-vivo transdermal absorption profile through pig skin for the entire formulation library. Each panel represent a set of three
formulations that shared similar phase composition and lipid content, but differed in surfactant system (n = 3; error bars indicate standard deviation).
https://doi.org/10.1371/journal.pone.0204531.g002
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observed variability is most probably due to the formulation composition, and its effect on the
release rate of vitamin K1. The overall trend was similar to the transmembrane diffusion pat-
tern. Again, the three formulations with 100% lipid content showed the highest cumulative
absorption at 12-hour end-point (up to 10.99% for O2 formulation; Fig 2A). Other studies for-
mulations did not reach values higher than 10%. Also, similar to transmembrane experiments,
W/O lotions showed the lowest transdermal absorption (1.4% at 12-hour time point for L.W/
O23; Fig 2H). A similar discrepancy was also observed between the transdermal absorption of
W/O and O/W lotions, and poloxamer and carbomer gels; however, the extent of the variabil-
ity was less significant, as it was mentioned before. The effect of surfactant system on the trans-
dermal absorption was even less significant, and formulations with different surfactant
systems did not perform differently in this set of studies. Small variations in this regard did not
seem to follow a particular trend.
Fig 3 presents the analysis of these two sets of experiments. The transmembrane and trans-
dermal studies showed a significant correlation (R = 0.71, p< 0.001; Fig 3A), which indicates
that diffusion from the vehicle is the rate-limiting step in the absorption process. This is in line
with the near complete transmembrane diffusion of free vitamin K1. Neither diffusion, nor
transdermal absorption significantly correlated with Viscosity (Fig 3B and 3C, respectively).
This is somewhat unexpected, and indicates that the viscosity of the dosage form is not a deci-
sive factor for the transdermal absorption of vitamin K1. While lower viscosity is reported to
enhance the transdermal absorption of different drugs (e.g., tenoxicam [18]), it seems that this
effect might not necessarily apply to transdermal delivery of every therapeutic agent. The lipid
content correlated with transmembrane diffusion (R = 0.48, p< 0.01) but not with transder-
mal absorption (R = 0.29; Fig 3D and 3E, respectively). This might be explained by an
enhanced interaction between the vehicle and the hydrophobic membrane with an increase in
Fig 3. Analysis of data. Statistical analysis of the in vitro and ex-vivo performance of the formulation library, including the correlation between viscosity and
transmembrane diffusion as well as transdermal absorption (A and B, respectively), lipid content and transmembrane diffusion as well as transdermal absorption (C and
D, respectively), the extent of transdermal diffusion at 12 hours and the percentage of transdermal absorption at the same time point (E), and a box graph comparison of
the mean diffusion and absorption for different category of formulations (F and G, respectively). R represents the correlation coefficient.
https://doi.org/10.1371/journal.pone.0204531.g003
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lipid content. A similar correlation has been reported for the lipophilicity of absorption
enhancers and percutaneous permeation [29]. However, this is obviously not the only factor
involved as for instance the transmembrane diffusion of O/W creams with 30% lipid content
(C.O/W19, 20, and 21) was significantly higher than the W/O lotions with 74% lipid content.
In addition to lipid content the effect of formulation composition (all oil, W/O, O/W, and all
aqueous) on the diffusion and absorption was also studied (Fig 3F and 3G, respectively). One-
way ANOVA showed significant difference between groups (p< 0.001), and the ranking of
transmembrane diffusion based on Tukey post hoc test was:
Oil > O=W W=O > Aqueous
Similar inter-group difference was observed for transdermal absorption (p< 0.01), and the
ranking of the groups was:
Oil > O=W W=O  Aqueous
The formulation with lowest transdermal absorption (L.W/O23) was stored in three differ-
ent storage conditions to evaluate the chemical stability of phytonadione in this formulation
(Fig 4). While samples stored in 37˚C and 95% humidity, and samples stored in ambient con-
ditions showed a rapid drop in phytonadione content (83.2% vitamin K1 remaining after 35
days, and 90.7% after 56 days, respectively), the samples stored in 4˚C and away from light
showed expected chemical stability in the studied period (~ 98% remaining after 180 days).
Conclusion
While transdermal delivery has been an objective for many formulation projects, we studied
the possibility of eliminating systemic absorption of vitamin K1 after topical administration
Fig 4. Chemical stability. The phytonadione content in different storage conditions versus time. The red dotted line represents the 90% lower limit, specified by USP
for vitamin K1 injectable emulsion.
https://doi.org/10.1371/journal.pone.0204531.g004
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(to inhibit the skin toxicity associated with EGFRIs) to minimize the risk of interference with
the therapeutic action of these anticancer agents used systemically in cancer treatment. Over-
all, the W/O lotion formulation L.W/O23 showed the lowest transdermal absorption at
24-hours’ time-point (10.97% diffusion) and the lowest transdermal absorption after 12 hours
(1.75% absorption) among the studied groups, and is being evaluated in vivo for the dermal
delivery of vitamin K1 in healthy volunteers. This formulation could be used concurrently or
after onset of therapy with EGFRIs without jeopardizing the patients’ response to cancer
treatment.
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